Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, W.-S.
Right arrow Articles by Chuang, L.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, W.-S.
Right arrow Articles by Chuang, L.-M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:376-380, 2002
© 2002 by the American Diabetes Association, Inc.

Pathophysiology/Complications
Original Article

Synthetic Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients

Wei-Shiung Yang, MD, PHD1,2, Chi-Yuan Jeng, MD, PHD3, Ta-Jen Wu, MD, PHD4, Sachiyo Tanaka, MD, PHD5, Tohru Funahashi, MD, PHD5, Yuji Matsuzawa, MD, PHD5, Jao-Ping Wang, BS1, Chi-Ling Chen, PHD6, Tong-Yuan Tai, MD, PHD1 and Lee-Ming Chuang, MD, PHD1,2

1 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
3 Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan
4 Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan
5 Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan
6 Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan

OBJECTIVE—Adiponectin, a plasma protein exclusively synthesized and secreted by adipose tissue, has recently been shown to have anti-inflammatory, antiatherogenic properties in vitro and beneficial metabolic effects in animals. Lower plasma levels of adiponectin have been documented in human subjects with metabolic syndrome and coronary artery disease. We investigated whether the level of this putative protective adipocytokine could be increased by treatment with a peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) agonist in diabetic patients.

RESEARCH DESIGN AND METHODS—Type 2 diabetic patients (30 in the treatment group and 34 in the placebo group) were recruited for a randomized double-blind placebo-controlled trial for 6 months with the PPAR-{gamma} agonist rosiglitazone. Blood samples were collected and metabolic variables and adiponectin levels were determined in all patients before initiation of the study.

RESULTS—In the rosiglitazone group, mean plasma adiponectin level was increased by more than twofold (P < 0.0005), whereas no change was observed in the placebo group. Multivariate linear regression analysis showed that whether rosiglitazone was used was the single variable significantly related to the changes of plasma adiponectin. The amount of variance in changes of plasma adiponectin level explained by the treatment was ~24% (r2 = 0.24) after adjusting for age, sex, and changes in fasting plasma glucose, HbA1c, insulin resistance index, and BMI.

CONCLUSIONS—Rosiglitazone increases plasma adiponectin levels in type 2 diabetic subjects. Whether this may contribute to the antihyperglycemic and putative antiatherogenic benefits of PPAR-{gamma} agonists in type 2 diabetic patients warrants further investigation.

Abbreviations: HOMA, homeostasis model assessment • TNF, tumor necrosis factor • PPAR-{gamma}, peroxisome proliferator-activated receptor-{gamma}


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
N. R Pinelli, R. Cha, M. B Brown, and L. A Jaber
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
Ann. Pharmacother., November 1, 2008; 42(11): 1541 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
X. Ruan, F. Zheng, and Y. Guan
PPARs and the kidney in metabolic syndrome
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan
Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice
Diabetes, August 1, 2007; 56(8): 2036 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. J. G. Hanley, D. Bowden, L. E. Wagenknecht, A. Balasubramanyam, C. Langfeld, M. F. Saad, J. I. Rotter, X. Guo, Y.-D. I. Chen, M. Bryer-Ash, et al.
Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2665 - 2671.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Wiecek, M. Adamczak, and J. Chudek
Adiponectin--an adipokine with unique metabolic properties
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma
Adiponectin and cardiovascular disease: state of the art?
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Lin, F. B. Hu, and G. Curhan
Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes
Diabetes Care, February 1, 2007; 30(2): 239 - 244.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. M. Utzschneider and S. E. Kahn
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens
Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1100 - E1105.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona
Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Shadid, C. D. A. Stehouwer, and M. D. Jensen
Diet/Exercise Versus Pioglitazone: Effects of Insulin Sensitization with Decreasing or Increasing Fat Mass on Adipokines and Inflammatory Markers
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3418 - 3425.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P. F. Pilch and N. Bergenhem
Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes
Mol. Pharmacol., September 1, 2006; 70(3): 779 - 785.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Sattar, G. Wannamethee, N. Sarwar, J. Tchernova, L. Cherry, A. M. Wallace, J. Danesh, and P. H. Whincup
Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis
Circulation, August 15, 2006; 114(7): 623 - 629.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Z. Punthakee, E. E. Delvin, J. O'Loughlin, G. Paradis, E. Levy, R. W. Platt, and M. Lambert
Adiponectin, Adiposity, and Insulin Resistance in Children and Adolescents
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2119 - 2125.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
Circulation, April 18, 2006; 113(15): 1888 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. G. Kim, O. H. Ryu, H. Y. Kim, K. W. Lee, J. A Seo, N. H. Kim, K. M. Choi, J. Lee, S. H. Baik, and D. S. Choi
Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.
Eur. J. Endocrinol., March 1, 2006; 154(3): 433 - 440.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
N. Bouatia-Naji, D. Meyre, S. Lobbens, K. Seron, F. Fumeron, B. Balkau, B. Heude, B. Jouret, P. E. Scherer, C. Dina, et al.
ACDC/Adiponectin Polymorphisms Are Associated With Severe Childhood and Adult Obesity
Diabetes, February 1, 2006; 55(2): 545 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
N. Saravanan, A. Haseeb, N. Z Ehtesham, and Ghafoorunissa
Differential effects of dietary saturated and trans-fatty acids on expression of genes associated with insulin sensitivity in rat adipose tissue
Eur. J. Endocrinol., July 1, 2005; 153(1): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Saraheimo, C. Forsblom, J. Fagerudd, A.-M. Teppo, K. Pettersson-Fernholm, J. Frystyk, A. Flyvbjerg, P.-H. Groop, and on behalf of the FinnDiane Study Group
Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy
Diabetes Care, June 1, 2005; 28(6): 1410 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
B. Cariou, J.-C. Fruchart, and B. Staels
Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists
The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 126 - 132.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
E. S. Kang, S. Y. Park, H. J. Kim, C. W. Ahn, M. Nam, B. S. Cha, S. K. Lim, K. R. Kim, and H. C. Lee
The Influence of Adiponectin Gene Polymorphism on the Rosiglitazone Response in Patients With Type 2 Diabetes
Diabetes Care, May 1, 2005; 28(5): 1139 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. A. Wagner, P. J. Larson, S. Weiss, J. L. Miller, T. W. Doebber, M. S. Wu, D. E. Moller, and K. M. Gottesdiener
Individual and Combined Effects of Peroxisome Proliferator-Activated Receptor and {gamma} Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers
J. Clin. Pharmacol., May 1, 2005; 45(5): 504 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
C. L. Winter, J. S. Lange, M. G. Davis, G. S. Gerwe, T. R. Downs, K. G. Peters, and B. Kasibhatla
A Nonspecific Phosphotyrosine Phosphatase Inhibitor, Bis(maltolato)oxovanadium(IV), Improves Glucose Tolerance and Prevents Diabetes in Zucker Diabetic Fatty Rats
Experimental Biology and Medicine, March 1, 2005; 230(3): 207 - 216.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
T. J Wilkin and L. D Voss
Metabolic syndrome: maladaptation to a modern world
J R Soc Med, November 1, 2004; 97(11): 511 - 520.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L.-M. Chuang, Y.-F. Chiu, W. H.-H. Sheu, Y.-J. Hung, L.-T. Ho, J. Grove, B. Rodriguez, T. Quertermous, Y.-D. I. Chen, C. A. Hsiung, et al.
Biethnic Comparisons of Autosomal Genomic Scan for Loci Linked to Plasma Adiponectin in Populations of Chinese and Japanese Origin
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5772 - 5778.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Guan
Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome
J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, T. Cascella, S. Di Biase, D. Labella, T. Russo, S. Savastano, F. Zullo, A. Colao, R. Vettor, et al.
Lack of an Association between Peroxisome Proliferator-Activated Receptor-{gamma} Gene Pro12Ala Polymorphism and Adiponectin Levels in the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5110 - 5115.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Furuhashi, N. Ura, N. Moniwa, Y. Shinshi, H. Kouzu, M. Nishihara, N. Kokubu, T. Takahashi, K.-i. Sakamoto, M. Hayashi, et al.
Possible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes
Diabetes Care, September 1, 2004; 27(9): 2217 - 2221.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Xydakis, C. C. Case, P. H. Jones, R. C. Hoogeveen, M.-Y. Liu, E. O. Smith, K. W. Nelson, and C. M. Ballantyne
Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: The Impact of Rapid Weight Loss through Caloric Restriction
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2697 - 2703.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. K. Bains, S. E. Wells, D. M. Flavell, K. M. Fairhall, M. Strom, P. Le Tissier, and I. C. A. F. Robinson
Visceral Obesity without Insulin Resistance in Late-Onset Obesity Rats
Endocrinology, June 1, 2004; 145(6): 2666 - 2679.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Sutinen, K. Kannisto, E. Korsheninnikova, R. M. Fisher, E. Ehrenborg, T. Nyman, A. Virkamaki, T. Funahashi, Y. Matsuzawa, H. Vidal, et al.
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E941 - E949.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. T. Lane
Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective
Am J Physiol Renal Physiol, March 1, 2004; 286(3): F442 - F450.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
W. B. Kinlaw and B. Marsh
Adiponectin and HIV-Lipodystrophy: Taking HAART
Endocrinology, February 1, 2004; 145(2): 484 - 486.
[Full Text] [PDF]

Home page
 HypertensionHome page
W. A. Hsueh and D. Bruemmer
Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease
Hypertension, February 1, 2004; 43(2): 297 - 305.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bajaj, S. Suraamornkul, P. Piper, L. J. Hardies, L. Glass, E. Cersosimo, T. Pratipanawatr, Y. Miyazaki, and R. A. DeFronzo
Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Muurling, A. M. van den Hoek, R. P. Mensink, H. Pijl, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance
J. Lipid Res., January 1, 2004; 45(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Sierksma, H. Patel, N. Ouchi, S. Kihara, T. Funahashi, R. J. Heine, D. E. Grobbee, C. Kluft, and H. F.J. Hendriks
Effect of Moderate Alcohol Consumption on Adiponectin, Tumor Necrosis Factor-{alpha}, and Insulin Sensitivity
Diabetes Care, January 1, 2004; 27(1): 184 - 189.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. B. Hu, A. Doria, T. Li, J. B. Meigs, S. Liu, A. Memisoglu, D. Hunter, and J. E. Manson
Genetic Variation at the Adiponectin Locus and Risk of Type 2 Diabetes in Women
Diabetes, January 1, 2004; 53(1): 209 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.G. Hanley, P. W. Connelly, S. B. Harris, and B. Zinman
Adiponectin in a Native Canadian Population Experiencing Rapid Epidemiological Transition
Diabetes Care, December 1, 2003; 26(12): 3219 - 3225.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, H. Uesugi, H. Sugiyama, A. Sugawara, K. Yamada, A. Shimatsu, et al.
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Diabetes Care, September 1, 2003; 26(9): 2493 - 2499.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry
Adiponectin: More Than Just Another Fat Cell Hormone?
Diabetes Care, August 1, 2003; 26(8): 2442 - 2450.
[Full Text] [PDF]

Home page
 DiabetesHome page
P. A. Kern, G. B. Di Gregorio, T. Lu, N. Rassouli, and G. Ranganathan
Adiponectin Expression From Human Adipose Tissue: Relation to Obesity, Insulin Resistance, and Tumor Necrosis Factor-{alpha} Expression
Diabetes, July 1, 2003; 52(7): 1779 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Furuhashi, N. Ura, K. Higashiura, H. Murakami, M. Tanaka, N. Moniwa, D. Yoshida, and K. Shimamoto
Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension
Hypertension, July 1, 2003; 42(1): 76 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, T. Cascella, G. Milan, R. Mioni, C. Pagano, F. Zullo, A. Colao, G. Lombardi, and R. Vettor
Adiponectin Levels in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2619 - 2623.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. K. S. Leow, C. L. Addy, and C. S. Mantzoros
Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976.
[Full Text] [PDF]

Home page
 DiabetesHome page
F. Pellme, U. Smith, T. Funahashi, Y. Matsuzawa, H. Brekke, O. Wiklund, M.-R. Taskinen, and P.-A. Jansson
Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients
Diabetes, May 1, 2003; 52(5): 1182 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Engeli, M. Feldpausch, K. Gorzelniak, F. Hartwig, U. Heintze, J. Janke, M. Mohlig, A. F.H. Pfeiffer, F. C. Luft, and A. M. Sharma
Association Between Adiponectin and Mediators of Inflammation in Obese Women
Diabetes, April 1, 2003; 52(4): 942 - 947.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. L. Addy, A. Gavrila, S. Tsiodras, K. Brodovicz, A. W. Karchmer, and C. S. Mantzoros
Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 627 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Tsunekawa, T. Hayashi, Y. Suzuki, H. Matsui-Hirai, H. Kano, A. Fukatsu, N. Nomura, A. Miyazaki, and A. Iguchi
Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance With Glimepiride in Elderly Type 2 Diabetic Subjects
Diabetes Care, February 1, 2003; 26(2): 285 - 289.
[Abstract] [Full Text] [PDF]